Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer

Takeo Kosaka, Akira Miyajima, Suguru Shirotake, Eriko Suzuki, Eiji Kikuchi, Mototsugu Oya

研究成果: Article

34 引用 (Scopus)

抄録

Purpose: There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation. Materials and Methods: We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution. Results: C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death. Conclusions: Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.

元の言語English
ページ(範囲)2376-2381
ページ数6
ジャーナルJournal of Urology
185
発行部数6
DOI
出版物ステータスPublished - 2011 6

Fingerprint

docetaxel
Castration
Androgens
Prostatic Neoplasms
Up-Regulation
Phosphatidylinositol 3-Kinase

ASJC Scopus subject areas

  • Urology

これを引用

Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. / Kosaka, Takeo; Miyajima, Akira; Shirotake, Suguru; Suzuki, Eriko; Kikuchi, Eiji; Oya, Mototsugu.

:: Journal of Urology, 巻 185, 番号 6, 06.2011, p. 2376-2381.

研究成果: Article

Kosaka, Takeo ; Miyajima, Akira ; Shirotake, Suguru ; Suzuki, Eriko ; Kikuchi, Eiji ; Oya, Mototsugu. / Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer. :: Journal of Urology. 2011 ; 巻 185, 番号 6. pp. 2376-2381.
@article{2125f8c50da54f6e8586aae75dba8791,
title = "Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer",
abstract = "Purpose: There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation. Materials and Methods: We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution. Results: C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death. Conclusions: Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.",
keywords = "androgen antagonists, docetaxel, drug resistance, neoplasm, prostate, prostatic neoplasms",
author = "Takeo Kosaka and Akira Miyajima and Suguru Shirotake and Eriko Suzuki and Eiji Kikuchi and Mototsugu Oya",
year = "2011",
month = "6",
doi = "10.1016/j.juro.2011.02.016",
language = "English",
volume = "185",
pages = "2376--2381",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer

AU - Kosaka, Takeo

AU - Miyajima, Akira

AU - Shirotake, Suguru

AU - Suzuki, Eriko

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2011/6

Y1 - 2011/6

N2 - Purpose: There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation. Materials and Methods: We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution. Results: C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death. Conclusions: Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.

AB - Purpose: There are still few effective therapeutic options for advanced prostate cancer. One of the most troublesome aspects of prostate cancer is that androgen dependent prostate cancer inevitably progresses to highly aggressive, life threatening castration resistant prostate cancer after androgen ablation therapy. To our knowledge it remains unknown how sensitivity to docetaxel changes during progression to more aggressive castration resistant prostate cancer under androgen ablation. Materials and Methods: We investigated sensitivity to docetaxel and phosphorylated Akt status in C4-2 and C4-2AT6 cells established at our institution. Results: C4-2AT6 cells established under androgen ablation conditions for 6 months showed significantly higher resistance to docetaxel than C4-2 cells in vivo and in vitro. Resistance was accompanied by increased phosphorylated Akt. In C4-2AT6 cells phosphorylated Akt activity was significantly up-regulated by docetaxel in a dose dependent manner. After treatment with docetaxel and a phosphatidylinositol 3-kinase/Akt inhibitor the sensitivity of C4-2AT6 cells to docetaxel markedly increased through enhanced apoptotic death. Conclusions: Findings indicated that up-regulation of phosphorylated Akt during androgen ablation and its further activation by docetaxel explains at least in part the resistance to docetaxel and progression to castration resistant prostate cancer under androgen ablation conditions.

KW - androgen antagonists

KW - docetaxel

KW - drug resistance

KW - neoplasm

KW - prostate

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=79955847465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955847465&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.02.016

DO - 10.1016/j.juro.2011.02.016

M3 - Article

C2 - 21511293

AN - SCOPUS:79955847465

VL - 185

SP - 2376

EP - 2381

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -